Search

About Us

About Us

American PAPR LLCis a protective equipment manufacturer. Our FELIX™100 PAPR is NIOSH-approved under the Public Health Emergency for PAPR100-N protection (99.97% filter efficiency level) effective against particulate aerosols free of oils. American PAPR LLC recommends the use of the FELIX™100 for healthcare workers responding to the COVID-19 virus. The device is manufactured and assembled in the USA within a medical equipment production facility operating under a comprehensive Quality System (QS). The FELIX™100 meets NIOSH requirements per 42 CFR Part 84 for respiratory protection against particulates.

American PAPR is a subsidiary of 3DBio Therapeutics, a biologics and bioprinting company with a focus on regenerative medicine that precision manufactures living tissues to allow replacement of each individual patient’s parts with tissues designed and created specifically for them. 3DBio has developed unique capabilities toward the creation of living tissue implants for therapeutic applications. The technology platforms include a full suite of features to meet the FDA’s requirements for therapeutic manufacturing, including novel and proprietary: 3D-bioprinter (GMPrint™), bio-ink (ColVivo™), and cell processes. In pre-clinical studies the platform has demonstrated the ability to generate functioning living tissues.

Management

Daniel Cohen, Ph.D. — Chief Executive Officer & Co-Founder

Daniel Cohen, Ph.D., is the CEO and Co-founder of 3DBio Therapeutics. Prior to 3DBio, Daniel was an Engagement Manager at McKinsey & Company in New York, where he focused on manufacturing, industrials, healthcare, and 3D printing. He received his Ph.D., as well as B.S. and M.S. degrees, in Mechanical Engineering from Cornell University, with minors in Biomedical and Electrical Engineering. Dr. Cohen was awarded both the National Science Foundation Graduate Research Fellowship, and the Department of Homeland Security Graduate Fellowship. At Cornell, he focused on bioprinting technology, completing his doctoral dissertation on 3D printing & bioprinting and holds numerous publications and patents in the field.

Nathaniel Bachrach, Ph.D. — Chief Scientific Officer & Executive Vice President

Nathaniel Bachrach, Ph.D., is Chief Scientific Officer and Executive Vice President of 3DBio Therapeutics. Prior to 3DBio, Nathaniel was the Vice President of Research & Technology at LifeCell (NASDAQ: LIFC), which was acquired by Allergan. Nathaniel came to LifeCell from Organogenesis. Dr. Bachrach received his Ph.D., as well as B.S. and M.S. degrees, in Mechanical Engineering from Columbia University in New York, where his research focused on cartilage and regenerative medicine.